Valuation: Candel Therapeutics, Inc.

Market Cap 663M 594M 548M 496M 928M 63.18B 943M 6.54B 2.61B 33.06B 2.49B 2.44B 105B P/E 2026 *
-6.14x
P/E 2027 * -7.45x
Enterprise Value 663M 594M 548M 496M 928M 63.18B 943M 6.54B 2.61B 33.06B 2.49B 2.44B 105B EV / Sales 2026 *
-
EV / Sales 2027 * 15.8x
Free-Float
85.21%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Candel Therapeutics, Inc.

1 day-0.63%
1 week+2.80%
Current month-17.48%
1 month-20.82%
3 months-8.35%
6 months+39.40%
Current year+52.48%
1 week 7.7
Extreme 7.7
8.93
1 month 7.7
Extreme 7.7
11.24
Current year 4.44
Extreme 4.44
14
1 year 4.35
Extreme 4.35
14
3 years 0.66
Extreme 0.66
14.6
5 years 0.66
Extreme 0.66
14.6
10 years 0.66
Extreme 0.66
14.78
Manager TitleAgeSince
Chief Executive Officer 66 2020-08-31
Director of Finance/CFO 41 2024-01-11
Chief Tech/Sci/R&D Officer 57 2022-09-11
Director TitleAgeSince
Director/Board Member 80 2017-08-31
Director/Board Member 66 2020-08-31
Chairman 70 2021-07-14
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 Free

Director

380 0.0005%
9/30/26 Free

Chairman

2,189 0.0029%
9/30/26 Free

Director

1,325 0.0017%
Change 5-day change 1-year change 3-year change Capi.($)
-0.63%+2.74%+56.92%+869.07% 663M
+0.34%-3.03%+37.45%+61.06% 64.14B
+0.98%+2.68%+12.25%+83.90% 55.53B
+1.75%+2.01%+13.30%+105.71% 53.03B
-1.81%-1.93%+25.31%+54.08% 45.99B
-0.64%-3.26%+17.46%+98.18% 42.45B
+0.52%+0.61%+225.46%+929.05% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-2.07%+42.73%+103.77%+90.26% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
Average -0.49%+3.80%+52.53%+233.09% 39.32B
Weighted average by Cap. -0.21%+3.13%+49.15%+161.30%

Financials

2026 *2027 *
Net sales - 41.92M 37.54M 34.64M 31.34M 58.61M 3.99B 59.56M 413M 165M 2.09B 157M 154M 6.62B
Net income -102M -90.96M -83.92M -75.94M -142M -9.67B -144M -1B -399M -5.06B -381M -373M -16.03B -92.33M -82.7M -76.29M -69.04M -129M -8.79B -131M -910M -363M -4.6B -346M -339M -14.57B
Net Debt - -
Projected Income Statement - Annual - Candel Therapeutics, Inc.
Logo Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Employees
55
Date Price Change Volume
26-10-29 US$8.620 -0.58% 524,261
26-10-28 US$8.670 +5.09% 663,859
26-10-27 US$8.250 +5.91% 928,461
26-10-26 US$7.790 -2.99% 849,302
26-10-23 US$8.030 -4.18% 1,184,816
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Candel Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.670USD
Average target price
22.11USD
Spread / Average Target
+155.03%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Candel Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. CADL Stock